Last reviewed · How we verify

Ketamine + Lidocaine — Competitive Intelligence Brief

Ketamine + Lidocaine (Ketamine + Lidocaine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist + local anesthetic combination. Area: Anesthesia; Pain Management.

phase 3 NMDA receptor antagonist + local anesthetic combination NMDA receptor; voltage-gated sodium channels Anesthesia; Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Ketamine + Lidocaine (Ketamine + Lidocaine) — State University of New York at Buffalo. Ketamine blocks NMDA receptors while lidocaine provides local anesthetic effects, together modulating pain signaling and potentially enhancing anesthetic efficacy.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ketamine + Lidocaine TARGET Ketamine + Lidocaine State University of New York at Buffalo phase 3 NMDA receptor antagonist + local anesthetic combination NMDA receptor; voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist + local anesthetic combination class)

  1. State University of New York at Buffalo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketamine + Lidocaine — Competitive Intelligence Brief. https://druglandscape.com/ci/ketamine-lidocaine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: